publication de travaux de recherche sur ncx 6560

http://cardiovascres.oxfordjournals.org/content/early/2012/02/23/cvr.cvs100.short
Nitric oxide enhances the anti-inflammatory and anti-atherogenic activity of atorvastatin in a mouse model of accelerated atherosclerosis


Abstract

Aims Aim of the present study was to assess whether the addition of a nitric oxide (NO)-donating moiety to atorvastatin enhances anti-inflammatory and anti-atherogenic effects in an animal model of endothelial dysfunction, systemic peroxidation and inflammation, and accelerated atherosclerosis.

Methods and Results Low-density-lipoprotein-receptor (LDLR)-/- mice kept on a high fat diet (HFD) for 16 weeks underwent photochemical-injury to the femoral artery with the local production of oxygen radicals. HFD markedly enhanced cholesterol, inflammatory biomarkers in plasma and in the femoral arterial wall, and enhanced atherosclerotic lesions in the aortic arch; inflammation and atherosclerosis were further increased by photochemically-generated oxygen radicals.

Treatment with the NO-donating atorvastatin NCX 6560 (11.7 mg/kg), was significantly more effective than atorvastatin (10 mg/kg) in reducing: lipid-rich lesions in the aortic arch (surface covered: atorvastatin=24±5%; NCX 6560=14.7±3.9%, p<0.05), the production of radical oxygen species (ROS) in aortas (DCF fluorescence intensity/mg of protein: atorvastatin=2419±136.7; NCX 6560=1766±161.2, p<0.05), femoral artery intima/media thickness (atorvastatin=1.2±0.11; NCX 6560=0.3±0.14, p<0.05), circulating IL-6 (atorvastatin=34.3±6.8 pg/ml; NCX 6560=17.7±14.4 pg/ml, p<0.05) and matrix-metalloproteinase (MMP)-2 in the arterial wall (atorvastatin=55.2±1.9 ng/µg of proteins; NCX 6560=45.8±2.6 ng/µg of proteins, p<0.05).

Conclusions In conditions of severe endothelial dysfunction, systemic peroxidation and inflammation and accelerated atherosclerosis atorvastatin, even at high doses, displays sub-optimal antiatherogenic and antiinflammatory effects while the addition of a NO-donating property confers enhanced and anti-atherogenic and antiinflammatory effects.
Key words

Atherosclerosis
Atorvastatin
Hypercholesterolemia
Inflammation
Peroxidation
Nitric oxide
NCX 6560

Cicletanine derivatives
A Ali, IK Sebhat, CL Franklin, KM Rupprecht… - US Patent 8,119,806, 2012

... 61/189,034 filed Aug. 15, 2008. JOINT RESEARCH AGREEMENT. The claimed invention was
made as a result of activities undertaken within the scope of a joint research agreement between
Merck & Co., Inc. and NicOx SA. The agreement was executed on Mar. 20, 2006. ...

http://www.freepatentsonline.com/8119806.html

Je ne sais pas si c'est consécutif à la nouvelle techno associant merck et nicox depuis peu ou la direction qu'ils prennent(l'agrement 2006 me perturbe mais le brevet est 2012)

et donc ? L'action a baissé today. Demain vos avis sur les annonces ?

vinsse a écrit:

Cicletanine derivatives
A Ali, IK Sebhat, CL Franklin, KM Rupprecht… - US Patent 8,119,806, 2012

... 61/189,034 filed Aug. 15, 2008. JOINT RESEARCH AGREEMENT. The claimed invention was
made as a result of activities undertaken within the scope of a joint research agreement between
Merck & Co., Inc. and NicOx SA. The agreement was executed on Mar. 20, 2006. ...

http://www.freepatentsonline.com/8119806.html

Je ne sais pas si c'est consécutif à la nouvelle techno associant merck et nicox depuis peu ou la direction qu'ils prennent(l'agrement 2006 me perturbe mais le brevet est 2012)

Bonsoir Vinsse,

Date de publication:21/02/2012 et Date de dépôt:27/07/2009 soit quatorze mois avant l’accord étendu , peut être que nous avons un des produits avec la nouvelle méthode. Je sais que tout les produits en cours avec l'ancienne méthode (16)ont été stoppés pour être repris avec la nouvelle méthode. On verra bien! et encore merci pour les infos!

salut

vu qu'il n'y aura certainement pas d'annonce ce matin, je dirai que le cours devrait descendre sur les prochains jours. mais je ne suis pas devin.

a suivre.